These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26717800)

  • 1. The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis.
    Bardin T; van de Laar MA
    Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS30-2. PubMed ID: 26717800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence.
    Bardin T
    Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS9-16. PubMed ID: 26717801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foreword.
    Bardin T; van de Laar MA
    Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS1. PubMed ID: 26717797
    [No Abstract]   [Full Text] [Related]  

  • 4. Canakinumab: a guide to its use in acute gouty arthritis flares.
    Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):401-6. PubMed ID: 23649936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.
    Schlesinger N; Mysler E; Lin HY; De Meulemeester M; Rovensky J; Arulmani U; Balfour A; Krammer G; Sallstig P; So A
    Ann Rheum Dis; 2011 Jul; 70(7):1264-71. PubMed ID: 21540198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
    So A; De Meulemeester M; Pikhlak A; Yücel AE; Richard D; Murphy V; Arulmani U; Sallstig P; Schlesinger N
    Arthritis Rheum; 2010 Oct; 62(10):3064-76. PubMed ID: 20533546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of flares and relief of urate burden with canakinumab and targeted urate-lowering therapy in tophaceous gouty arthritis.
    Fanouriakis A; Karantanas A; Fragouli E; Repa A; Sidiropoulos P
    Rheumatology (Oxford); 2014 Apr; 53(4):764-6. PubMed ID: 24185764
    [No Abstract]   [Full Text] [Related]  

  • 8. Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases.
    Avram A; Duarte C; Santos MJ; Papagoras C; Ritis K; Scarpioni R; Schmidt WA; Skendros P
    Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS17-29. PubMed ID: 26717798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1 as a therapeutic target in gout.
    Dumusc A; So A
    Curr Opin Rheumatol; 2015 Mar; 27(2):156-63. PubMed ID: 25633244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra.
    Joosten LA; Crişan TO; Azam T; Cleophas MC; Koenders MI; van de Veerdonk FL; Netea MG; Kim S; Dinarello CA
    Ann Rheum Dis; 2016 Jun; 75(6):1219-27. PubMed ID: 26174021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difficult-to-treat gouty arthritis: a disease warranting better management.
    Schlesinger N
    Drugs; 2011 Jul; 71(11):1413-39. PubMed ID: 21812506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.
    Cronstein BN; Sunkureddi P
    J Clin Rheumatol; 2013 Jan; 19(1):19-29. PubMed ID: 23319019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doliroside A attenuates monosodium urate crystals-induced inflammation by targeting NLRP3 inflammasome.
    Wei H; Hu C; Xie J; Yang C; Zhao Y; Guo Y; Mei Z; Chen L; Lan Z
    Eur J Pharmacol; 2014 Oct; 740():321-8. PubMed ID: 25064339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The etiology and management of gout].
    Pazár Maldonado B; So A
    Z Rheumatol; 2012 Feb; 71(2):127-36; quiz 137. PubMed ID: 22370804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in the treatment of gouty arthritis.
    Fang ZH; Waizy H
    Orthop Surg; 2013 Feb; 5(1):6-12. PubMed ID: 23420740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.
    Schlesinger N; Alten RE; Bardin T; Schumacher HR; Bloch M; Gimona A; Krammer G; Murphy V; Richard D; So AK
    Ann Rheum Dis; 2012 Nov; 71(11):1839-48. PubMed ID: 22586173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gouty arthritis: understanding the disease state and management options in primary care.
    Sunkureddi P
    Adv Ther; 2011 Sep; 28(9):748-60. PubMed ID: 21894471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.
    Chakraborty A; Van LM; Skerjanec A; Floch D; Klein UR; Krammer G; Sunkara G; Howard D
    J Clin Pharmacol; 2013 Dec; 53(12):1240-51. PubMed ID: 24122883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy.
    Schlesinger N
    Semin Arthritis Rheum; 2012 Oct; 42(2):155-65. PubMed ID: 22542277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics considerations for gout treatments.
    Richette P; Frazier A; Bardin T
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):949-57. PubMed ID: 24809930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.